Skip to main content

Advertisement

SpringerLink
Log in

Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

The survival benefit of postoperative adjuvant transcatheter arterial chemoembolization (TACE) remains controversial.

Aims

We aim to investigate the survival effect of postoperative adjuvant TACE on the prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients (stage B, the Barcelona Clinic Liver Cancer staging).

Methods

Sixty consecutive HBV-related HCC patients (stage B) from February 2006 to May 2009 undergoing surgical resection were included in this study. Of these 60 patients, 34 patients underwent surgery only (Group A) and 26 patients underwent surgery plus TACE (Group B). We followed-up until May 2013. Overall survival rates as well as prognostic factors were analyzed by the Kaplan–Meier method, the log-rank test or Cox’s proportional hazard model. All patients’ data were collected from the hospital medical records, which were described precisely after accurate clinical samples detection.

Results

The 1-, 2-, and 3-year overall survival rates in surgery-only group were 58.8, 32.4 and 12.6 %, and the rates in surgery plus TACE group were 73.1, 61.5, and 48.9 %, respectively (P = 0.033). The median survival time of the two groups after surgery and surgery plus TACE was 15.0 months [95 % confidence interval (CI) 10.714–19.286] and 35.0 months (95 % CI 20.974–49.026). In multivariate analysis, hemoglobin, HBeAg, peripheral blood regulatory T cells and tumor size were independent prognostic elements for HBV-related HCC patients (stage B).

Conclusions

Postoperative adjuvant TACE improves the survival of patients with HBV-related HCC (stage B) after curative resection compared to surgery only.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rilling WS, Drooz A (2002) Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radiol 13:S259–S263

    Article  PubMed  Google Scholar 

  2. Lencioni R, Chen XP, Dagher L et al (2010) Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15:42–52

    Article  CAS  PubMed  Google Scholar 

  3. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044

    Article  CAS  PubMed  Google Scholar 

  4. Lai MY, Chen DS, Chen PJ et al (1998) Status of hepatitis B virus DNA in hepatocellular carcinoma: a study based on paired tumor and nontumor liver tissues. J Med Virol 25:249–258

    Article  Google Scholar 

  5. Kim BK, Park JY, Kim do Y et al (2008) Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 28:393–401

    Article  CAS  PubMed  Google Scholar 

  6. Chuma M, Hige S, Kamiyama T et al (2009) The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 44:991–999

    Article  CAS  PubMed  Google Scholar 

  7. Yang T, Lu JH, Zhai J et al (2012) High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol 38:683–691

    Article  CAS  PubMed  Google Scholar 

  8. Kubo S, Hirohashi K, Tanaka H et al (2001) Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg 18:26–33

    Article  CAS  PubMed  Google Scholar 

  9. Ohkubo K, Kato Y, Ichikawa T et al (2002) Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 94:2663–2668

    Article  PubMed  Google Scholar 

  10. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524

    Article  PubMed  Google Scholar 

  11. El-Serag HB, Marrero JA, Rudolph L et al (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763

    Article  PubMed  Google Scholar 

  12. Hanazaki K, Kajikawa S, Shimozawa N et al (2002) Hepatic resection for hepatocellular carcinoma in diameter of ≥10 cm. Hepatogastroenterology 49:518–523

    PubMed  Google Scholar 

  13. Ng KK, Vauthey JN, Pawlik TM et al (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364–373

    Article  PubMed  Google Scholar 

  14. Lin CT, Hsu KF, Chen TW et al (2010) Comparing hepatic resection and transarterial chemoembolization for barcelona clinic liver cancer (BCLC) Stage B hepatocellular carcinoma: change for treatment of choice? World J Surg 34:2155–2161

    Article  PubMed  Google Scholar 

  15. Tsai TJ, Chau GY, Lui WY et al (2000) Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 127:603–608

    Article  CAS  PubMed  Google Scholar 

  16. Zhu AX (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11:790–800

    Article  CAS  PubMed  Google Scholar 

  17. Yeo W, Mok TS, Zee B et al (2005) A randomized phase III study of Doxorubicin versus cisplatin/interferon alpha-2b/Doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532–1538

    Article  CAS  PubMed  Google Scholar 

  18. Leung TW, Patt YZ, Lau WY et al (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676–1681

    CAS  PubMed  Google Scholar 

  19. Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33:S134–S138

    Article  PubMed  Google Scholar 

  20. Okada S (1998) Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 27:1743–1744

    Article  CAS  PubMed  Google Scholar 

  21. Mathurin P, Raynard B, Dharancy S et al (2003) Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 17:1247–1261

    Article  CAS  PubMed  Google Scholar 

  22. Tanaka K, Shimada H, Togo S et al (1999) Use of transcatheter arterial infusion of anti-cancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 46:1083–1088

    CAS  PubMed  Google Scholar 

  23. Fukuda S, Okuda K, Imamura M et al (2002) Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 131:300–310

    Article  PubMed  Google Scholar 

  24. Xi T, Lai EC, Min AR et al (2012) Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology 59:1198–1203

    PubMed  Google Scholar 

  25. Pringle JH (1908) Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg 48:541–549

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Liao KF, Lai SW, Lin CY et al (2011) Risk factors of recurrence after curative resection of hepatocellular carcinoma in Taiwan. Am J Med Sci 341:301–304

    Article  PubMed  Google Scholar 

  27. Chang SKY, Hlaing WW, Yu RQ et al (2012) Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection. Singap Med J 53:32–35

    CAS  Google Scholar 

  28. Lai CL, Ratziu V, Yuen MF et al (2003) Viral hepatitis B. Lancet 362:2089–2094

    Article  CAS  PubMed  Google Scholar 

  29. Chen CH, Huang GT, Yang PM et al (2006) Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 42:2524–2529

    Article  PubMed  Google Scholar 

  30. Shijo H, Okazaki M, Koganemaru F et al (1991) Influence of hepatitis B virus infection and age on mode of growth of hepatocellular carcinoma. Cancer 67:2626–2632

    Article  CAS  PubMed  Google Scholar 

  31. Lai EC, Lo CM, Fan ST et al (1998) Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133:183–188

    Article  CAS  PubMed  Google Scholar 

  32. Chen L, Zhang Q, Chang W et al (2012) Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 48:1977–1987

    Article  CAS  PubMed  Google Scholar 

  33. Chen JD, Yang HI, Iloeje UH et al (2010) Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747–1754

    Article  PubMed  Google Scholar 

  34. Ren ZG, Lin ZY, Xia JL et al (2004) Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 10:2791–2794

    Article  PubMed Central  PubMed  Google Scholar 

  35. Zhong C, Guo RP, Li JQ et al (2009) A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III a hepatocellular carcinoma. J Cancer Res Clin Oncol 135:1437–1445

    Article  PubMed  Google Scholar 

  36. Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628–636

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the National Natural Science Foundation of China (No. 81001002, 30973438, 81101754 and 81201861), Tianjin Natural Science Foundation (No. 09JCYBJC10400) and Tianjin Health Bureau Foundation (No. 2010KZ7).

Conflict of interest

We declare that we have no conflict of interest.

Ethical statement

We declare that all study participants provided informed consent, and the study design was approved by the Tianjin Anti-Cancer Association and Tianjin Medical University Cancer Hospital and Institution Ethics Committee and have been performed in accordance with the ethical standards laid down in the 1975 Declaration of Helsinki.

Author information

Authors and Affiliations

  1. Department of Interventional Treatment, Tianjin Medical University Cancer Hospital and Institution, Tianjin Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin, 300060, China

    F. Li, Z. Guo, Y. Zhang, H. Wang, T. Si & H. Yu

  2. Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    X. Zhang

  3. Laboratory of Molecular Neuro-Oncology, Texas Children’s Cancer Center, Houston, TX, USA

    L. Qi

Authors
  1. F. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Si
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z. Guo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, F., Guo, Z., Zhang, Y. et al. Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study. Ir J Med Sci 184, 753–759 (2015). https://doi.org/10.1007/s11845-014-1164-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-014-1164-6

Keywords

Search

Navigation